Background Primary Obesity Surgery Endolumenal (POSE) is a novel bariatric endoscopic procedure that has been shown to reduce weight safely through 12 months. The study investigated potential mechanisms of weight loss following POSE. Methods Patients with class I-II obesity received transmural plications in the gastric fundus and distal gastric body. Patients were evaluated at baseline and at 2-and 6-month follow-up with gastric-emptying (GE) scintigraphy, a validated test of intake capacity (kcal) and plasma glucose homeostasis hormones/gastrointestinal peptides. Weight was recorded through 15 months. Mean data and 95 % CIs are reported. Regression modeling assessed variables that influenced total weight loss (%TWL) and excess weight loss (%EWL).
Introduction
Obesity is a major global health problem in the twenty-first century. Although bariatric surgery has been shown to achieve long-term weight loss and comorbidity resolution superior to that of conventional obesity treatment (i.e., diet, exercise, pharmacotherapy) [1] [2] [3] and it is associated with a very low mortality rate (0.1 to 0.4 %) [4, 5] , its use has been limited by concerns regarding morbidity and access [6] . Less-invasive approaches are needed.
The minimally invasive Incisionless Operating Platform™ (IOP; USGI Medical, San Clemente, CA, USA) has been used to carry out a variety of gastroendoscopic procedures, including the Repair of Surgery Endolumenal (ROSE) procedure to treat weight gain and repair complications following Roux-en-Y gastric bypass (RYGB). Recently, the IOP has been used as a platform to perform the Primary Obesity Surgery Endolumenal (POSE) procedure, which involves endolumenal placement of durable, full-thickness tissue plications in the fundus and additional plications in the distal body. In an earlier, prospective, single-center, observational study, 45 obese patients who received the POSE procedure lost substantial weight (mean 15.5 % total weight loss [TWL] and 49.4 % excess weight loss [EWL] with >80 % achieving ≥25 % EWL at 6-month follow-up) with no intraoperative adverse events, conversions, failed procedures, or postoperative re-hospitalizations [7] . In another POSE study in 116 obese patients who were available for follow-up at 12 months, a mean TWL of 15.1 % and EWL of 44.9 % were attained without serious adverse events [8] .
There are no data yet on longer term weight loss after POSE. Moreover, the underlying mechanisms of weight loss after the POSE procedure are unknown. It has been hypothesized that the POSE procedure might induce weight loss by reducing caloric intake capacity (meal size). However, meal size depends on complex gastric and post-gastric neural and humoral signaling [9, 10] . The procedure's plications in the fundus might limit postprandial fundus accommodation to a meal, which may increase intragastric pressure. Increased pressure might enhance the firing of gastric nerve endings, signaling satiation and prompting early meal termination [11, 12] . It is also possible that distal gastric body plications placed with the POSE procedure could impair antral contractions, delaying gastric emptying and further enhancing gastric satiation signals [13] .
This study was designed to investigate specific mechanisms of weight loss following the POSE procedure. Changes in meal size, gastric emptying, and gut hormones involved in short-term control of food intake and weight loss after POSE were studied.
Methods

Study and Patients
This was a single-center study of a prospective series of obese patients. All patients provided written informed consent prior to any study procedure in accordance with Teknon Medical Center (Barcelona, Spain) Ethics Board requirements and good clinical practices guidelines outlining patient protections stipulated by the Declaration of Helsinki. The study was registered as #NCT01679158 in the US clinicaltrials.gov database.
Eligible patients were required to be 21-59 years old with a BMI ≥30 and <40 kg/m 2 . Patients were obliged to have had no significant weight change (±5 kg) in the last 6 months. Patients were enrolled if they had no contraindications for general anesthesia, successfully completed the physical and psychological assessment that confirmed their candidacy for a bariatric procedure and the ability to comply physically and mentally with the visit schedule and ancillary testing required for the study. Patients were also required to agree not to undergo any additional weight-loss intervention, procedures, or liposuction for at least 18 months following study enrollment and not to take any prescription or over-the-counter weightloss medication for at least 1 year after the POSE procedure.
Patients were excluded if they had a history of bariatric, gastric, or esophageal surgery; esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments; moderate to severe gastroesophageal reflux disease; active peptic ulcer or hiatal hernia of >3 cm; gastrointestinal (GI) motility disorder or pancreatic insufficiency/disease; history of inflammatory disease of the GI tract; history of type 2 diabetes for >2 years or uncontrolled type 2 diabetes (HbA 1C >7.0); a history or current use of insulin or insulin derivatives for treatment of diabetes; severe coagulopathies, hepatic insufficiency, or cirrhosis; known hormonal or genetic cause for obesity; a history of, or current, drug or alcohol abuse; or had quit smoking within the last 6 months or planned to quit smoking in the next year. Also, patients were excluded if they were currently taking medication for depression, psychosis, or other mood or eating disorder; currently taking corticosteroids; non-ambulatory or had significantly impaired mobility; pregnant; participating in another clinical study; or had worked for, or were a first-degree relative of, the investigator, study institution, or study support staff.
Study Design
In this study, the MOTIlity, hormonal impact, satiety, and weight changes with VArying procedural TEchniques (MOTIVATE) trial patients underwent GI physiological studies (i.e., meal size, gastric emptying, glucose homeostasis, gut hunger/satiety peptides) at baseline (prior to the POSE procedure), 2, and 6 months post-procedure. Weight, height, BMI, blood pressure, adverse events, and changes in medications were recorded at baseline and at all post-POSE follow-up evaluations at months 1, 2, 4, 6, 8, 10, 12, and 15. In-office nutritional assessment and counseling were offered during follow-up.
Endoscopic Equipment and Surgical Procedure
POSE is performed with a minimally invasive suite of gastroendoscopic instruments developed by USGI Medical (San Clemente, CA, USA) (Fig. 1a) . The equipment and procedure have been described in detail in previous reports [7, 8] .
Between 8 and 11 suture-anchor plications were placed with the IOP (Fig. 1b) in the fundus with the intent of forming two parallel rows, or "bridges" (Fig 1c) ; 3-4 additional sutureanchor plications were placed in the distal body using one of the three techniques. Figure 1d illustrates one of these techniques to help induce gastric dysmotility by reducing the size of the antral inlet.
Postoperative Care
Patients were discharged within 24 h, as deemed medically indicated. During the first 4 weeks post-procedure, patients were advised to maintain a customized, calorierestricted diet that transitioned from liquids to soft solids to full solids with a specified targeted amount of protein and fat and minimum quantity of liquids. Walking exercise (10-15 min 2-3 times/day) was encouraged during the first 4 postoperative weeks, and patients were instructed to increase their exercise in the fifth week to an aerobic regimen of 30-45 min 5 times/week.
Caloric Intake Capacity
To assess caloric intake capacity (meal size) before and after the POSE procedure, we used a standardized nutrient drink test [11, 14, 15] . Patients ingested a nutritional drink (Ensure®, Abbott Nutrition, Lake Forest, IL; 1 mL=1.5 kcal) at a constant rate of 30 mL/min. The glass was constantly filled with a perfusion pump so that the patient was unaware of the volume being ingested. Patients were instructed to maintain consumption at the fill rate and note their sensation of satiety using a graphical classification scale ranging from 0-5 with verbal descriptors (0=no symptoms; 5=maximum fullness). Patients were told to stop ingestion when the score of 5 was reached. Caloric intake capacity was summarized as the number of calories ingested until the point of maximum satiation was reached.
Caloric intake measured by the nutrient drink test has been shown to correlate well with caloric intake during a buffet a b c d meal [15] . The nutrient drink test has shown good reproducibility and sensitivity to change and has been tested in healthy, normal weight, and obese populations [16, 17] .
Gastric Emptying
Gastric emptying of a solid meal was assessed using the gold standard measurement, scintigraphy [13, 18] . Hormone measurements of PYY3-36 and total ghrelin were performed with radioimmunoassay, and leptin was measured using spectrophotometry (Diagnostics Biochem Canada, Inc., Ontario, Canada). Samples were collected using EDTA tubes and adding several commercial protease inhibitors to measure active hormones (Millipore DPPIV inhibitor, sigma protease inhibitor cocktail, and Pefabloc SC® [Roche Diagnostics, Mannheim, Germany).
Plasma changes in hunger/satiation peptides in response to a standard meal were summarized, as in previous studies [15, 18] by computing the ratio of the highest (lowest for ghrelin) postprandial plasma level over the fasting plasma level (fed/ fast ratio) and the postprandial proportional change (fed−fast/ fast×100) for each hormone or peptide evaluated.
Statistical Analysis
Patient baseline characteristics and operative outcomes were summarized using descriptive statistics. Continuous variables are reported as mean, standard deviation (SD), standard error (SE), and range. Outcome continuous variables are reported as mean (95 % CI). Categorical variables are reported as counts and percentages.
Excess body weight (EBW) at baseline was calculated as the difference between weight (kg) at baseline and ideal body weight (IBW). IBW was calculated for a BMI of 25. Weight loss after the POSE procedure was assessed as proportional total body weight loss (%TWL) ([pre-procedure weight minus post-procedure weight/pre-procedure weight]×100) and proportional %EWL ([pre-procedure weight minus postprocedure weight/pre-procedure EBW]×100).
Postoperative changes were assessed using match-paired analyses. The specified primary endpoint for gastric emptying comparisons was, as in previous studies [16] , initial gastric emptying; that is, gastric nutrients retained 10 min after the standard meal (GR10). Subgroup analyses for weight loss were not performed on the three distal body configurations due to the small sample size.
Multivariate regression analyses were performed to identify significant independent predictors of %EWL at 15 months (dependent variable) following the procedure. We explored whether changes in meal size, GE, or hunger/satiation factors (independent variables) might predict sustained weight loss after the POSE procedure. The primary endpoints selected for this analysis were, as used in previous studies [15, 16] , initial GR10 and plasma fasting levels and postprandial changes of hunger satiation hormones. The rationale to select GR10 as the primary gastric emptying endpoint was the hypothesis that meal size depends on signals that arise early during meal ingestion. We included as covariates age, sex, weight, height, and BMI. Regression models were explored using backward, forward, and mixed stepwise approaches selected based on the adjusted R 2 with the least number of independent variables. Least-square mean estimates±SEM from the best-fitting regression model are reported.
Results
Patient Characteristics
Between February and May 2012, the POSE procedure was performed on 18 patients (14 women, 4 men) with a 100 % (18/18) follow-up at 1-6 months, 89 % (16/18) at 9 months, and 83 % (15/18) at both 12 and 15 months. Patients had a mean age of 39.3±9.8 years (range 21-53). The mean baseline weight and BMI were, respectively, 102.7±10.7 kg (89-131) and 36.3±2.3 kg/m 2 (32-40). All patients reported overeating and 67 % (n=12) binge eating.
Operative Outcomes
The mean number of total suture anchors placed was 14.3±1.1 (range 12-16), with a mean of 9.7±0.8 (8-11) fundal anchors and 3.9±0.2 (3-4) distal body anchors. The mean operative time was 51±9 min (39-70). All patients were discharged within 24 h following the procedure. There were no postoperative complications or unscheduled endoscopies.
Weight Outcomes
A significant and progressive weight loss after the POSE procedure was maintained during the length of the entire study. Figure 2 shows mean %TWL and %EWL at baseline and during follow-up. At 
Caloric Intake Capacity
Caloric intake capacity (meal size) was significantly reduced after the POSE procedure. Thus, to reach maximum satiation, patients drank on average 901 kcal (685, 1117) before and 473 kcal (345, 600) and 574 (418, 730) at 2 and 6 months after the POSE procedure, respectively (both p<0.001 vs. baseline) (Fig. 3) .
Gastric Emptying
Two months following the POSE procedure, the gastric emptying rate was delayed during the first hour after the standard meal compared to before the POSE procedure (p<0.05). However, on average, gastric emptying function completely normalized over 2 h 6 months after POSE (Fig. 4 ). All subjects emptied almost 100 % by the 2-h time-point.
Glucose Homeostasis and Satiation Peptides
As might be expected, circulating leptin levels and glucose homeostasis improved after the POSE procedure (Table 1) . Fasting and postprandial responses of ghrelin and PYY also improved (Fig. 5) . Hence, fasting levels of ghrelin increased at 2 and 6 months after the POSE procedure compared to baseline (p<0.05). Also, postprandial inhibition of ghrelin was significantly enhanced from −7 % before the procedure to Gastric emptying curves before and at 2 and 6 months (n=18) after POSE. Two months after the POSE procedure, gastric emptying was prolonged during the first 60 min after a meal compared with baseline. By 6-month follow-up, patients' gastric emptying profile was similar to their pre-procedure profile −15 % 6 months after the procedure (p=0.005). PYY fasting levels also decreased after POSE vs. baseline (p<0.05) and postprandial PYY stimulation was significantly increased from +15 to +34 % 6 months after POSE (p=0.04).
Predictors of Weight Loss 15 Months After POSE
As explained in the Methods, the physiological changes after the POSE procedure were explored that might influence weight loss after surgery. Regression modeling was used that incorporated as independent variables, sex, age, height, weight, BMI, GR10, and also plasma endocrine factors and hunger/satiation peptides during fasting and in the postprandial period. The best-fitting model for %EWL 15 months postprocedure (R 2 =66 %; p=0.006) included basal, pre-procedure BMI, GR10, and PYY postprandial change 2 months postprocedure. Thus, weight loss at 15 months was greater in lower-weight patients, those who experienced a greater GR10 at 2 months, and those who experienced higher PYY postprandial change. Hence, independent of basal weight, greater impact on gastric function, and postprandial PYY response 2 months after the POSE procedure significantly influenced sustained weight loss. Figure 6 shows the independent additive effects of postprandial PYY change and gastric retention on %EWL at 15 months following the procedure.
Discussion
This small observational study was not intended to focus on weight measurement following the POSE procedure, but rather to obtain insights into its mechanisms of action. However, the weight loss observed seems to support that of an earlier study that showed that the POSE procedure resulted in substantial weight loss in obese patients with 6 months of follow-up [7] , and it suggests that this weight loss might be sustained at least through 15-month follow-up. In the MOTI-VATE study, mean EWL at 6 and 15 months post-procedure was 56.5 and 63.7 %, respectively. The magnitude of weight loss following the POSE procedure seems superior to that achieved with currently available pharmacotherapy and intensive lifestyle interventions [19] , similar to that achieved with laparoscopic adjustable gastric banding (LAGB) and lower than that associated with RYGB at 12 months of follow-up [20, 21] . Interestingly, the mean 15-month TWL following the POSE procedure (19.1 %) was significantly higher than the modest 5 % TWL shown to significantly reduce weightrelated comorbidities, including diabetes, hypertension, and dyslipidemia [22] . At 15-month follow-up, >90 % (14/15) of evaluable patients and 78 % (14/18) of all enrolled patients (based on a conservative assumption that the three patients lost to follow-up before 15 months would have failed this endpoint) had achieved ≥25 % EWL.
For the first time, the MOTIVATE study explored potential mechanisms underlying weight loss after the POSE procedure. The data show that there is a statistically significant post-procedure change in satiation (caloric intake capacity); thus, patients needed significantly fewer calories to reach the point of maximum satiation. This was observed early, at 2 months, and was maintained at 6 months post-POSE. Caloric intake capacity as measured in this study has been shown to be a significant predictor of weight loss after RYGB or sleeve gastrectomy (LSG) [14] . Reduction in caloric capacity is critical to a successful and sustainable weight-loss procedure. In addition to some reduction in gastric volume, it is hypothesized that the primary mechanism by which caloric intake is reduced is through the prevention of fundal accommodation by the suture-anchors, triggering earlier satiety. The Fast plasma levels measured in fasting conditions, Fed maximum (minimum for ghrelin) levels during the fed period (2 h) measured, PP ratio postprandial ratio (fed/fast), PP Δ postprandial delta (fed−fast/fast×100), POSE primary obesity surgery endolumenal, Δ change vast majority of POSE procedure patients at our hospital continue to subjectively report earlier satiety and less hunger at 6 and 12 months post-procedure. Satiation is known to depend on a complex array of gastric and post-gastric signals [20] [21] [22] . Meal size is influenced by gastric volume [11, 12] , gastric emptying, and the postprandial response of ghrelin and PYY [14] . In this study, circulating levels of both pre-and post-meal ghrelin and PYY were seen to change significantly after the POSE procedure. These changes were observed as early as 2 months post-procedure and were maintained at 6 months, possibly contributing to early and sustained weight loss.
Ghrelin is a gut peptide secreted primarily from the gastric fundus that stimulates appetite and increases food intake [23] . In normal-weight individuals, ghrelin increases before meals and decreases quickly afterwards [24] . The current study showed that pre-meal circulating ghrelin increased after the POSE procedure. It has been shown that obese individuals have lower levels of circulating ghrelin [25] and that circulating ghrelin levels increase in response to weight loss by caloric restriction [26] . Thus, it is conceivable that observed changes in pre-meal circulating ghrelin may have been related to weight loss rather than to the POSE procedure itself.
The MOTIVATE study also demonstrated that pre-meal circulating PYY levels decreased after POSE, whereas postprandial PYY increased significantly at 2 and 6 months following POSE. PYY, which signals satiety, is secreted from L cells located predominantly in the distal intestinal tract in response to nutrients [27] . Gastric emptying was not changed at 6 months post-POSE compared to pre-POSE. Thus, gastric emptying would not explain the differences observed in our study on postprandial PYY levels after POSE. PYY is released within 10 min of food intake, before ingested nutrients reach the distal small intestine and colon, where the greatest concentrations of PYY are found [28] . This suggests that initial postprandial release of PYY is under neural control. Moreover, altered vagal afferent sensitivity has been suggested in obese patients [29] . It is conceivable that improved vagal afferent sensitivity after POSE, as suggested occurs after other bariatric interventions [30] , might enhance the response of PYY to nutrients, as observed in the current study. More interestingly, we observed that the postprandial PYY increase at 2 months was predictive of weight loss at 15 months. These findings are in concordance with the known biological functions of PYY [27] and with data from bariatric surgery studies. Studies have shown better long-term weight outcomes after RYGB or laparoscopic adjustable gastric band LAGB in patients with enhanced PYY postprandial response [28, [31] [32] [33] . The MOTIVATE study data suggest that increased PYY release in response to nutrients following the POSE procedure may be a relevant mechanism of decreased caloric intake and the weight loss observed with this procedure, similar to that observed following several bariatric surgery techniques.
We also observed that patients show a transient delay of gastric emptying of solids early, 2 months after undergoing POSE. This delay is conceivably the result of the physiological inflammatory response to the presence of transmural plications in the gastric wall. The presence of microinflammatory changes in the submucosal and muscular layers of the stomach alters sensory and motor responses in the gastrointestinal tract [34] . When inflammation resolves, gastric function may return to its previous state, as observed in the current study with the normalization of gastric emptying 6 months after POSE. Interestingly, our data suggest that those who experienced transient delay in gastric emptying were more likely to lose more weight and to maintain their weight loss at 15-month follow-up. This observation should be considered with caution; however, once acute inflammation is resolved, permanent Bsensitization^of afferent nerves in the gut wall may occur [35, 36] . Peripheral sensitization is known to cause early satiation and increased postprandial fullness in many patients with functional dyspepsia [37, 38] . Hence, it is not inconceivable that patients undergoing POSE who present with more intense inflammatory responses at the gastric wall, and thus, a transient delay in gastric emptying, sensitization may have occurred that might explain their permanent enhanced satiation perception in response to food. Further studies of the POSE procedure's mechanisms of action are needed to clarify this issue.
In conclusion, the MOTIVATE study provides additional evidence that the endoscopic POSE procedure results in substantial early weight loss sustained through 15 months. The study also suggests that potential mechanisms of weight loss following the POSE procedure may include significant changes in neuro-hormonal circuits involved in the regulation of food intake. Additional research with larger sample sizes and longer follow-up is needed to determine the effectiveness of the POSE procedure in promoting durable weight loss and resolving obesity-related comorbidities. Investigation is also needed to determine the therapeutic profile and cost effectiveness of POSE compared with bariatric surgical procedures. Fig. 6 Surface plot showing the independent effects of postprandial increase in PYY (ΔPYY) (x-axis) and at 10-min post-meal gastric retention (GR10) (z-axis) on percentage excess weight loss (%EWL) (black surface) at 15 months (n=15) after the POSE procedure. Note that weight loss is greater in those with higher postprandial ΔPYY and those with increased GR10 (arrow). On the contrary, weight loss is lower in those with a lesser increase in postprandial ΔPYYand decreased GR10 (arrowhead)
